Evidence map›Paper›PMID 38770155›Full record

ArticleDrugs and drug candidates2023

Schlesinger Nailed It! Assessing a Key Primary Pharmacodynamic Property of Phages for Phage Therapy: Virion Encounter Rates with Motionless Bacterial Targets.

Stephen T Abedon

Abstract read
In one paragraph

Article in Drugs and drug candidates, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Microscopic phage adsorption assay: High-throughput quantification of virus particle attachment to host bacterial cells.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stephen T AbedonDepartment of Microbiology, The Ohio State University, Mansfield, OH 44906, USA.ORCID 0000-0001-9151-2375

Funding

The impact of bacteriophage therapy on wound infection dynamicsR01AI169865 · NIAID · OHIO STATE UNIVERSITY · PI Daniel J Wozniak · 2022 to 2026
$3.7M
Phage extracellular polysaccharide depolymerases to combat Pseudomonas aeruginosa biofilmsR21AI156304 · NIAID · OHIO STATE UNIVERSITY · PI ABEDON, STEPHEN T · 2021 to 2022
$429k
NIAID NIH HHS R01 AI169865NIAID NIH HHS R21 AI156304
6 · The paper itself

Abstract

Bacteriophages (phages) are viruses of bacteria and have been used as antibacterial agents now for over one-hundred years. The primary pharmacodynamics of therapeutic phages can be summed up as follows: phages at a certain concentration can reach bacteria at a certain rate, attach to bacteria that display appropriate receptors on their surfaces, infect, and (ideally) kill those now-adsorbed bacteria. Here, I consider the rate at which phages reach bacteria, during what can be dubbed as an 'extracellular search'. This search is driven by diffusion and can be described by what is known as the phage adsorption rate constant. That constant in turn is thought to be derivable from knowledge of bacterial size, virion diffusion rates, and the likelihood of phage adsorption given this diffusion-driven encounter with a bacterium. Here, I consider only the role of bacterial size in encounter rates. In 1932, Schlesinger hypothesized that bacterial size can be described as a function of cell radius (

Indexed as

bacterial aggregatesbacterial clustersbacteriophage therapybiofilmphage-antibiotic synergyphage therapy

Identifiers

PMID38770155
PMCPMC11104014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.